Abstract
Most rheumatic diseases resist traditional therapeutic interventions. Novel biologicals show considerable promise as antirheumatic agents but do not lend themselves to delivery as drugs. Gene therapy promises to harness the therapeutic potential of proteins by acting as a biological drug delivery system. Considerable progress has been made in the use of genes to treat animal models of RA, and a human trial of this technology is scheduled to begin this year.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-5 |
| Number of pages | 5 |
| Journal | Proceedings of the Association of American Physicians |
| Volume | 108 |
| Issue number | 1 |
| State | Published - Jan 1996 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'The promise of a new clinical trial--intra-articular IL-1 receptor antagonist.'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS